Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Skin problems like acne, dry skin, and nail and hair changes are common in patients taking EGFR inhibitors.

This study found that EGFR and MEK inhibitors may induce acneiform skin toxicities by interacting with the skin bacterium Cutibacterium acnes to increase IL-36γ and IL-8 production in keratinocytes.

This review discusses the common dermatologic side effects of epidermal growth factor receptor inhibitors and provides practical guidance for recognizing and managing these effects; it reports no new clinical results.

In this study, researchers reviewed cases of EGFR inhibitor-induced folliculitis decalvans and reported the first known occurrences associated with afatinib in three female NSCLC patients, highlighting the importance of early diagnosis and management to improve patient quality of life.

This study suggests that cutaneous lymphadenoma is a distinct benign lymphoepithelial tumor characterized by androgen receptor expression, hair follicle stem cell markers, and common EGFR gene mutations.

This study found that epidermal growth factor receptor and mitogen activated protein kinase inhibitors down-regulate PD-L1 expression in human hair follicles, which may contribute to sterile folliculitis in treated patients.

This review highlights that chemotherapy-induced skin toxicities from EGFR inhibitors in breast cancer treatment can significantly impact patient quality of life and treatment adherence, emphasizing the importance of proactive management and patient discussions.

ATR04-484 ointment shows promise for treating skin issues from cancer therapies.

Some lung cancer patients treated with EGFR inhibitors may develop a hair loss condition similar to folliculitis decalvans.

The enzyme PA-PLA1α is important for proper hair follicle development.

This review discusses the classification, pathogenesis, and management of skin, hair, nail, and mucosal changes due to EGFR inhibitors, emphasizing the importance of informing patients to improve therapy compliance.

This review summarizes adverse events associated with EGFR-targeting cancer therapies, such as skin rashes and lung disease, and reports no new clinical results.

EGFR signaling is essential for ear cell regeneration in both birds and mammals.

This study found that EGFR-targeted cancer therapy can cause skin toxicities by disrupting epidermal signaling, allowing microbiota invasion and inflammation, but identified a potential treatment approach using FGF7 or SOS expression to restore barrier integrity.

This review observes that trichomegaly, a newly described side effect of EGFR inhibitors causing excessive eyelash and scalp hair growth, persists in some patients whose tumors respond positively to the therapy.

This review discusses the range of cutaneous side-effects caused by EGFR inhibitors in cancer therapy and explores available treatment options, without reporting new clinical findings.

This case report describes how discontinuing the EGFR inhibitor gefitinib led to rapid improvement of erosive scalp pustules in a woman with non-small-cell lung cancer, despite previous antibiotic and steroid treatment failures.

This study reported that the most common skin side effect of epidermal growth factor receptor inhibitors was a papulopustular rash, treatable with symptom-targeted therapies, while drug suspension was rarely needed.

In this study, Waved-5 mice with reduced EGFR signaling showed nearly normal skin and hair follicle function but experienced a transient reduction in subcutaneous fat.

This article explores potential mechanisms of acneiform skin eruptions linked to EGFR inhibition in cancer patients, focusing on EGFR's role in controlling IL-1-dependent inflammation at hair follicles, but reports no clinical results.

EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.

In this study, researchers observed that EGFR deficiency in the epidermis affects gene expression related to cell differentiation and structure, highlighting spatial and temporal roles of EGFR during skin and hair follicle development.

This study found that XiaoZhenFang (XZF) reduced skin toxicities caused by Erlotinib in a mouse model, likely through mechanisms involving inflammation and EGFR-related pathways.

In this study, EREG promoted hair growth by activating specific receptors in cell and animal models, indicating it may be a potential treatment for hair loss.

In this study, researchers found that disrupting EGFR signaling in mice led to increased inflammation and hair follicle damage but that inhibiting the JAK-STAT1 pathway could restore hair growth and skin function.

In this study, Gsdma1/2/3 knockout mice showed reduced epidermal hyperplasia and inflammation when induced by PMA, which was attributed to decreased EGFR-Stat3/Akt signaling due to a decrease in related ligands.

This study observed that piperonylic acid activated key signaling pathways in dermal papilla cells and increased hair growth markers, and a clinical trial showed users of a piperonylic acid formulation had more hair than those using a placebo, suggesting its potential for treating hair loss.

This study found that EGFR inhibitors and ligands did not significantly affect the expression of inflammatory biomarkers in cultured sebocytes, except for a notable increase in IL-1 expression with EGF treatment.

This manuscript describes two case reports of preterm newborns with a rare homozygous mutation in the epidermal growth factor receptor, leading to severe health issues and early mortality despite supportive care.

In this study, epidermal EGFR ablation in a mouse model led to significant local and systemic inflammatory responses, highlighting EGFR's role in maintaining skin immuno-homeostasis.